Company: CSTL
Filing Date: 2025-03-28
Form Type: PRE 14A
Source: 0001447362-25-000050
Chunk: 1

Company: CASTLE BIOSCIENCES INC
Filing Date: 2025-03-28
Form: PRE 14A
Chunk 1
---
332 million, representing growth of 51% over 2023, and saw 36% growth in our year-over-year total test report volume.

We are confident in our ability to sustain our strong momentum that is shaping the future of patient care and delivering lasting value for our stakeholders.

We appreciate your ongoing engagement and encourage you to review the materials that follow to ensure your shares are represented at our meeting. Thank you for your continued investment in Castle and for your support that is helping us improve the care and lives of patients.

Sincerely,

#### Derek J. Maetzold
Founder, President & CEO

| “Our full-year 2024 revenueincreased by 51%over 2023 to$332 million, exceeding our 2024 revenue guidance of $320-330 million.” |

#### iCastle Biosciences 2024 Proxy Statement
| Letter from our   
 Independent Chair |

#### TO MY FELLOW STOCKHOLDERS,
On behalf of the Board of Directors, I’d like to echo Derek's gratitude for your continued investment in Castle. The Board is committed to advancing Castle’s strategic initiatives aimed at generating lasting value for stockholders and believes that maintaining open, honest dialogue is essential to achieving these objectives. As such, the Board values your input to inform sound decision-making impacting the governance and future of Castle.

The Proxy Statement that follows includes information about the proposals to be voted on during the 2025 Annual Meeting. We encourage you to use one of the options outlined in this document to cast your votes and thank you in advance for your time in doing so.

Sincerely,

#### Daniel M. Bradbury
Independent Chair of the Board

| ”The Board is committed to helping Castle deliver on its growth objectives to continue tocreate value for its stakeholders, including patients, clinicians, employees and investors.” |

#### Castle Biosciences 2024 Proxy Statementii
| DEAR STOCKHOLDER:                                                                                                                                                                                                                                                                                                                                                                                                                             
 You are cordially invited to attend the 2025 annual meeting of stockholders (including any adjournments, continuations or postponements thereof, the “Annual Meeting”) of Castle Biosciences, Inc., a Delaware corporation. The Annual Meeting will be held on Thursday, May 22, 2025, at 10:00 a.m. Central Time at the San Luis Resort, Spa and Conference Center, 5222 Seawall Boulevard, Galveston, TX 77551, for the following purposes: |     | 1 |     | To elect the three Class III directors